In the in vivo study, Wistar rats were randomly divided into five groups. All rats received intraperitoneal (IP) injection of silica suspension (250 mg/100 g body weight) on day 0. The rats of group 1 (control group) were injected with vehicle IP every day for 14 days. The rats of groups 2, 3, and 4 were injected with PTX (4 mg/100 g body weight) IP every day for 3, 7, and 14 days, respectively. The rats in group 5 received an intravenous infusion of PTX (8 mg/100 g body weight) every day for 7 days. On the 15th day after silica injection, all rats were sacrificed. Their parietal and visceral peritoneums were removed and processed for pathology, and the severity of fibrosis was measured and scored. ♦♦ ♦♦ ♦ Results: In vitro, PTX inhibited serum-stimulated HPFB growth (maximum was 93% at 1 mg PTX/mL) in a dosedependent manner. Collagen synthesis by HPFB was reduced (47% at 1 mg PTX/mL), and collagen I and III mRNA expression in HPFBs was suppressed by PTX. The PTX did not affect the MMP (including MMP-1, MMP-8, and MMP-13) activities of HPFBs. The mechanism of PTX was through increasing cAMP by its phosphodiesterase inhibiting activity. In vivo, the severity of fibrosis was significantly reduced in groups 4 and 5 compared to group 1 (p < 0.05). ♦♦ ♦♦ ♦ Conclusion: These results suggest that PTX can inhibit growth of and collagen synthesis by HPFBs in vitro. The fibrosis derived from silica-induced peritonitis in vivo was also ameliorated by PTX. Therefore, pentoxifylline may have the potential to be used to treat peritoneal fibrosis in patients on CAPD.
lation of dialysate, and finally to peritoneal dialysis failure. Fibroblast hyperplasia and increased extracellular matrix have been observed in peritoneal biopsies from patients on long-term CAPD (8, 9) . Therefore, agents that can inhibit fibroblast proliferation and collagen synthesis might be useful in preventing the process of peritoneal fibrosis.
Pentoxifylline (PTX) is a xanthine derivative and possesses the ability of inhibiting phosphodiesterase (10) . Clinically, it is used for the treatment of peripheral vascular and cerebrovascular diseases (10) . It can inhibit the proliferation and synthesis of glycosaminoglycan and collagen by fibroblasts derived from normal human skin tissue and from patients with fibrotic disorders (11, 12) . Pentoxifylline can also reduce postoperative peritoneal fibrosis and adhesion formation in rats (13) . Therefore, we conducted a study to evaluate the effects of PTX on human peritoneal fibroblast (HPFB) growth and collagen synthesis. We further studied the effects of PTX on animals injected IP with silica dioxide to induce peritonitis, which is characterized by peritoneal fibroblast hyperplasia and collagen accumulation (14) . We found that PTX can suppress not only peritoneal fibroblast proliferation and collagen synthesis in vitro, but also silica-induced peritoneal fibrosis in vivo.
MATERIALS AND METHODS

MATERIALS
Trypsin-EDTA, RPMI-1640 medium, glutamine, and trypan blue were obtained from Gibco (Grand Island, New York, USA). Culture flasks and plates were purchased from Corning (Corning, New York, USA) and precoated with Vitrogen 100 (Celtrix Lab., Palo Alto, California, USA) before cells were loaded. Fetal calf serum (FCS) was obtained from Biochrom KG (Berlin, Germany). Triton X-100, bovine serum albumin, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), penicillin, streptomycin, insulin, ascorbic acid, β-aminopropionitrile, pepsincontaining acetic acid, and silica dioxide (particle diameter 0.1 -10 µm) were bought from Sigma (St. Louis, Missouri, USA). [ 3 H]-Proline was obtained from NEN Dupont (Boston, Massachusetts, USA). Monoclonal antibodies to human desmin, vimentin, cytokeratin, and factor VIII-related antigen were from Dako (Kyoto, Japan). The PTX was bought from Hoechst Co. (Strasbourg, Germany).
HPFB CULTURE
Specimens of human omentum were obtained from patients, with their informed consent, undergoing elective abdominal surgery. The omentum of each patient was normal. The omentum was disaggregated by a previously described method (15) . Briefly, a piece of omentum was washed in sterile phosphate-buffered saline (PBS) and then incubated with trypsin-EDTA (0.05%) for 20 minutes at 37°C with continuous rotation. After incubation, the omentum and the suspension were centrifuged at 50g for 5 minutes at 4°C, the supernatant was discarded and the omentum was washed in PBS. Then the omentum was incubated with trypsin-EDTA (0.1%) for 40 minutes at 37°C with continuous stirring, centrifuged, and the supernatant discarded as above. The washed omentum was incubated again with trypsin-EDTA (0.1%) for 40 minutes at 37°C, but after centrifuging, both the omentum and the supernatant were removed. The cell pellet was then washed in RPMI-1640 medium containing 20% FCS, penicillin 100 U/mL, streptomycin 100 µg/mL, and insulin 30 µg/mL. The cells were resuspended in the same medium and seeded into a 75-cm 2 flask. After 7 -10 days, the cells became confluent and were subcultured with medium containing 20% FCS.
The HPFBs in monolayer cultures showed both bipolar and multipolar morphology and stained positively for vimentin and myosin by immunohistochemistry. Less than 5% of cultured cells were stained for cytokeratin, factor VIII, or desmin. Therefore, HPFB cultures were excluded from contamination by epithelial, endothelial, and mesothelial cells. All experiments were conducted at least three times with cells from different donors.
CELL PROLIFERATION ASSAY
The modified MTT assay was used (16) . The MTT assay is based on the ability of living cells to take up and their mitochondria to reduce MTT to form the blue formazan product. The amount of MTT taken up by HPFBs (measured by absorbance at 570 nm) was found to be highly correlated with the number of cells, nearly linearly in the range from 2 × 10 3 cells/well to 3.2 × 10 4 cells/well in 96-well plates ( Figure 1 ). Cells growing in log phase were trypsinized and resuspended in RPMI-1640 medium containing 20% FCS. For the proliferation assay, we loaded 2000 cells/well (in 180 µL of suspension) into 96-well plates. Various concentrations of agents were added after overnight plating. The medium and drugs were changed every 3 days. After additional incubations of 48 -144 hours, 20 µL MTT solution (5 mg/mL in PBS) was added to each well of a 96-well plate. After another incubation at 37°C for 4 hours, the medium was replaced with 100 µL of pure ethanol. Absorbance at the reference wavelength of 630 nm and test wavelength of 570 nm was measured using an ELISA reader. Five replicates of each assay were performed. To calculate the percentage of inhibition by MTT assay, the following formula was used:
abs of (test dose -initial plating)  abs of (control -initial plating)  where abs = absorbance.
CELL VIABILITY TEST
To exclude a toxic effect of PTX on HPFBs, cell viability was assessed by the trypan blue exclusion method in 24-well plates after incubating at various doses of PTX for 2 -6 days. Trypan blue was added directly to each well to determine both the number of dead cells in the supernatant and the proportion of adherent dead cells. All experiments were done in triplicate.
TEST OF INJURY TO HPFB PLASMALEMMA
To exclude toxicity of PTX to the integrity of HPFB plasmalemma, leakage of lactate dehydrogenase (LDH) from the cytosol of the HPFBs was measured. The HPFBs were plated at a density of 2 × 10 4 cells/ well in a 24-well plate and grown to a confluent monolayer. After being washed twice in warm PBS, the medium was replaced with 0.5 mL RPMI-1640 medium with 0.5% FCS. Various concentrations of PTX were added, and 0.015% Triton X-100 was added as a positive control. The plates were incubated for 2, 4, and 6 days and then the LDH activity of the supernatant was measured using the enzymatic method (17) . All experiments were done in triplicate.
COLLAGEN SYNTHESIS
The HPFBs were plated at a density of 1.5 × 10 4 cells/well in a 96-well plate with 200 µL medium supplemented with 20% FCS. After 48 hours of incubation, the cells became confluent. The medium was then replaced with 20% FCS-supplemented medium containing 50 µg/mL ascorbic acid, with or without different concentrations of PTX. After an additional incubation of 48 hours, cultures were labeled with 0.5 µCi [ 3 H]-proline (100 Ci/mmole) and 50 µg/mL β-aminopropionitrile for the final 24 hours of incubation. [ 3 H]-Proline incorporation into pepsin-resistant salt-precipitated collagen was determined as previously described (18) . After termination of incubation, [ 3 H]-proline-labeled collagen was extracted from each well with the addition of pepsin-containing acetic acid (final concentration 1 mg/mL in 1 mol/L acetic acid) and was purified by successive salt precipitation at acidic and neutral pH in the presence of carrier collagen. The final precipitates were dissolved in 0.5 mol/L acetic acid, incorporated into a scintillation cocktail, and counted in a liquid scintillation counter. The numbers of cells were counted simultaneously using the MTT assay in identically treated microplates, and the collagen synthetic amount was factored by the number of cells in the same treated well. All experiments were done in triplicate.
NORTHERN BLOT ANALYSIS
The HPFBs were cultured in a 50-cm 2 dish with 20% FCS-containing RPMI to a confluent monolayer. After growth arrest for 2 days with serum-free RPMI, the supernatants were replaced with serum-free RPMI with various concentrations of PTX. At various time intervals, the total RNA was isolated using the acid guanidinium thiocyanate-phenol-chloroform method. RNA (10 µg) was then electrophoresed on a 1% agarose gel containing 1.0 mol/L formaldehyde in MOPS buffer (0.2 mol/L morpholino-propanesulfonic acid, 0.05 mol/L Na acetate, 0.01 mol/L EDTA). Equivalency of sample loading and lack of degradation were verified by ethidium bromide staining of 28 S and 18 S rRNA bands. The RNA was transferred to nylon membranes using overnight capillary action and then fixed in a UV cross-linker. Hybridization of the Northern blots was performed with a cRNA probe for 1.5-kb human type I collagen [procollagen α1 (I)] and type III collagen [procollagen α1 (III)]. The procedures were the same as we described previously (18) . The signal intensity recorded on x-ray film was quantified by computerized densitometry. The blots were also probed with cRNA for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) to control for variations in RNA loading and transfer.
1 -
× 100, HPFBs (2 × 10 5 per well) were loaded into a 6-well plate and cultured in medium supplemented with 20% FCS. After 3 -5 days, the cells became confluent, they were washed twice with warm RPMI-1640 medium, and then various concentrations of agents were added. After 5 minutes' incubation, the supernatants were discarded and ice-cold 95% methanol/5% formic acid solution was added to each well. After 30 minutes' incubation at 4°C, the supernatants were evaporated and cAMP was measured using an enzyme immunoassay kit (Cayman Chemical, Ann Arbor, Michigan, USA). The cells of each well were lysed with 0.1 N NaOH and the protein contents were measured by bicinchoninic acid assay, with bovine serum albumin as the standard. All experiments were done in duplicate.
MMP ACTIVITY ASSAYS
HPFBs were cultured in a 50-cm 2 dish with 20% FCS-containing RPMI to a confluent monolayer. After washing twice with serum-free RPMI-1640 medium, the HPFBs were treated with various concentrations of PTX. The supernatants were then collected and frozen for 24 hours and 48 hours. The activities of MMP-1, MMP-8, and MMP-13 were measured using commercial kits (Amersham Pharmacia Biotech UK, Buckinghamshire, England). The kits used monoclonal antibodies to capture MMP-1, MMP-8, or MMP-13, and then assayed their activities by reacting with a specific chromogenic peptide substrate (19) . The cells of each well were lysed with 0.1 N NaOH and the protein contents were measured by bicinchoninic acid assay, with bovine serum albumin as the standard. All experiments were performed in duplicate.
ANIMAL MODEL OF SILICA-INDUCED PERITONITIS
Female Wistar rats weighing 200 -250 g were randomly allocated to one of five groups of six animals each ( Figure 2 ). All the animals were anesthetized with ketamine hydrochloride. Silica dioxide was sterilized in a drying oven (120°C, 1 hour) and suspended in normal saline. The silica suspension was instilled (250 mg/100 g body weight) IP in all rats on day 0, with care not to penetrate the bowel. An internal jugular vein cannula was inserted into each rat of group 5 and a line was kept in its back for further intravenous drug delivery. The rats of group 1 (control group) were injected IP with vehicle every day for 14 days. The rats in groups 2, 3, and 4 received PTX (4 mg/ 100 g body weight) IP every day for 3, 7, and 14 days, respectively. Group 5 received a 2-hour intravenous infusion of PTX (8 mg/100 g body weight pumped at 0.1 mg/minute) every day, from day 1 to day 7. The rats were given access to food ad libitum and were kept under a 12-hour light and dark cycle. On day 15 all rats were sacrificed. Peritoneal cavities were exposed and tissue with silica nodules and parietal and visceral peritoneum specimens were taken and processed for pathology. The tissue sections were stained with hematoxylin and eosin, or van Gieson, and the severity of fibrosis was measured and scored.
STATISTICS
All data are expressed as mean ±SD. Comparison of dose effect was done with a one-way ANOVA and post hoc test. The scores of fibrosis severity were analyzed using the nonparametric Mann-Whitney test. A p value less than 0.05 was considered significant.
RESULTS
PTX INHIBITS HPFB GROWTH AND COLLAGEN SYNTHESIS
At concentrations below 1 mg/mL, PTX caused a dose-dependent inhibition of HPFB growth (Figure 3) . The percentage inhibition for concentrations of 0.1 to 1 mg/mL was 9% to 93%. Cell viability was confirmed by the trypan blue test, which showed no differences in the nonadherent and adherent cell fractions between control and PTX-treated wells. All wells contained > 99% viable cells. After 2-, 4-, and 6-day incubation periods in PTX-treated wells, levels of LDH Figure 2 -Animal study protocol: 30 female Wistar rats were randomly allocated to 1 of 5 groups of 6 rats each. Silica suspension was instilled (↓; 250 mg/100 g body weight) intraperitoneally (IP) in all rats on day 0. Beginning on day 1, the rats of groups 2, 3, and 4 received pentoxifylline (PTX; shaded area; 4 mg/100 g body weight) IP every day for 3, 7, and 14 days, respectively. Group 5 received PTX (hatched area; 8 mg/100 g body weight) through intravenous infusion pump every day, from day 1 to day 7. On day 15 all rats were sacrificed (X). were not elevated, excluding the possibility of cell membrane damage by PTX (data not shown). Collagen synthesis of HPFBs was suppressed by PTX in a dosedependent manner (Figure 4 ). The amount of collagen synthesis by 1 mg/mL of PTX-treated HPFBs was about 40% that of the control. mRNA expression of types I and III collagen was measured after adding PTX. Densitometry showed that PTX reduced both procollagen α1 (I) and procollagen α1 (III) mRNA expression, while GAPDH mRNA was not affected in HPFBs ( Figure 5 ). Maximal decrease of these two mRNA levels was observed at 32 hours after the addition of 1.0 mg/mL PTX (about 50% decreases).
To study the effect of PTX on collagen degradation, we examined the activities of MMP after PTX treatment. We studied three important metalloproteinases related to interstitial collagen remodeling:
MMP-1 (collagenase 1), MMP-8 (collagenase 2), and MMP-13 (collagenase 3). As shown in Table 1 , PTX did not affect the activities of these three MMPs.
The results of intracellular cAMP levels are shown in Table 2 . The cAMP levels were elevated by PTX in a dose-dependent manner after 5 minutes of incubation. PGE 1 (an adenine cylase activator) increased cAMP levels at 10 µmol/L, which was potentiated by the presence of 1.0 mg/mL PTX or 0.5 mmol/L IBMX (a phosphodiesterase inhibitor). On combining various concentrations of PTX and 0.5 mmol/L IBMX, there was no significant elevation of cAMP compared Figure 5 -Northern blot analysis of mRNA isolated from human peritoneal fibroblasts. The RNA blots were hybridized with procollagen α1 (I) and GAPDH, or procollagen α1 (III) and GAPDH cRNA probes. Cells were treated with agents for 24 and 32 hours. Lanes 1, 2, and 3 represent the control, 0.3 mg/mL pentoxifylline (PTX), and 1.0 mg/mL PTX, respectively, after 24 hours' incubation. Lanes 4, 5, and 6 represent control, 0.3 mg/mL PTX, and 1.0 mg/mL PTX, respectively, after 32 hours' incubation. with IBMX alone. These results indicate that the mechanism of PTX on HPFBs might be similar to IBMX as a phosphodiesterase inhibitor.
PTX REDUCES SILICA-INDUCED GRANULOMATOUS FIBROSIS
After IP silica instillation, most rats developed detectable ascites. The silica-induced nodules were scattered in the peritoneum and the omentum. Microscopically, the tissues showed typical silica-induced pathologic changes of peritoneal fibrosis, including fibroblast proliferation, prominent collagen fibers, and obvious granulomatous inflammation. The severity of silica-induced granuloma and fibrosis was measured and scored by a pathologist without knowing the label of the specimens. The score of each specimen was graded by the amount of collagen fibers, stained in dark red, in the granuloma. Specimens of mild fibrosis (collagen fibers less than 10% of the whole granuloma field) were scored as 1. Specimens of moderate fibrosis (collagen fibers between 10% and 50% of the whole granuloma field) were scored as 2. Specimens of severe fibrosis (collagen fibers more than 50% of the whole granuloma field) were scored as 3. Examples of each grade of granulomatous fibrosis by van Gieson stain are shown in Figure 6 . Each animal was given a cumulative score, which was measured by averaging the scores of 20 granulomas. The scores of the five study groups are listed in Table 3 . The severity of fibrosis in PTX-treated rats (groups 4 and 5) was significantly less than that of control (group 1). The antifibrogenic effect of PTX was more obvious with increasing doses of PTX, as the score of group 4 was significantly less than that of group 2. The effect of intravenous injection of PTX (group 5) was similar to that of IP injection of PTX (group 4).
DISCUSSION
CAPD depends on the functional and morphological integrity of the peritoneum serving as the dialyzing membrane. After long-term use of CAPD, the peritoneal membrane thickens and becomes fibrotic (20) . It has been shown that solute transfer increases while ultrafiltration declines with time on CAPD (21). The progressive increase in peritoneal fibrosis might be one of the reasons for impaired membrane function after long-term CAPD [reviewed in Ref. (22)]. On the cellular level, this membrane consists mainly of two resident cell populations: the peritoneal mesothelium, which forms a superficial cell monolayer facing the peritoneal cavity; and fibroblasts, the major cell population of the peritoneal interstitium. The peritoneal mesothelial cell has been identified as a major source of immunoregulatory molecules involved in the initiation and control of peritoneal inflammation (23, 24) , and of peritoneal fibrosis (25) . However, its role in the pathogenesis of peritoneal fibrosis is not clear. The peritoneal fibroblast has been considered a major participant in peritoneal fibrosis (15) . The process of fibrosis depends on the interaction of fibroblasts and the different components of the extracellular matrix (26) . In addition, fibroblasts express cytokine receptors, generate various types of cytokines upon activation (27) , and produce prostaglandins and extracellular matrix components upon stimulation by cytokines (28) . Also, interleukin (IL)-1, Figure 6 -Examples of each grade of granulomatous fibrosis by van Gieson stain, magnified 100× (A,C,E) and 400× (B,D,F). Each specimen's score was graded by the amount of collagen fibers, stained in dark red, in the granuloma. Specimens of mild fibrosis (collagen fibers less than 10% of the whole granuloma field) were scored as 1 (A,B). Specimens of moderate fibrosis (collagen fibers between 10% and 50% of the whole granuloma field) were scored as 2 (C,D). Specimens of severe fibrosis (collagen fibers more than 50% of the whole granuloma field) were scored as 3 (E,F). tumor necrosis factor alpha (TNFα), and PGE 2 are involved in the regulation of α 1 (I) procollagen gene expression of human lung fibroblasts (29) . In studies with HPFBs in cell culture systems, stimulation of HPFBs with increasing doses of IL-1, or TNFα, or both, resulted in a dose-and time-dependent induction of IL-6 mRNA and an increase in immunoreactive IL-6 protein secreted by HPFBs (30) . Moreover, infected peritoneal dialysis effluent caused fibroblast hyperplasia, which could potentially contribute to profibrotic processes during CAPD (15) . Therefore, fibroblasts may play an important role in peritoneal fibrosis during peritoneal dialysis. Pentoxifylline reduced fibroproliferation and myofibroblastic differentiation in an animal model of liver fibrosis (31) . Pentoxifylline inhibits human renal fibroblasts on cell proliferation, extracellular matrix synthesis, and myofibroblastic differentiation (32) . In the present study, we further demonstrated that PTX inhibited growth of and collagen synthesis by peritoneal fibroblasts in culture. We also demonstrated that PTX suppressed peritoneal fibrosis in a silica-induced model in which peritoneal fibroblasts are considered to play an important role in the pathogenesis of peritoneal fibrosis (14) . Our previous study disclosed that PTX also inhibited growth of and collagen synthesis by peritoneal mesothelial cells (33) . Other investigators showed that PTX inhibits IP adhesions after intestinal resection in rats (13) . All these results suggest that PTX may have a role in preventing peritoneal fibrosis in patients with CAPD.
Dibutyryl cAMP (a cAMP analogue) suppresses lung fibroblast proliferation and collagen production (34) . Increasing intracellular cAMP also inhibits connective tissue growth factor-induced collagen synthesis in renal fibroblasts (35) . In the in vitro part of the present study, PTX was shown to increase cAMP through inhibiting phosphodiesterase. Our previous studies showed that cAMP can inhibit cell growth and collagen synthesis (18) ; PTX has similar effects on human peritoneal mesothelial cells via its activity of inhibiting phosphodiesterase (33) . Therefore, it is justifiable to conclude that the pharmacodynamic mechanism of PTX on HPFBs could be a phosphodiesterase inhibitor. The pharmacokinetic profile of PTX showed that absorption by the oral route is rapid (10) . However, the oral route was not used in the present study because oral intake by rats is less predictable, especially during peritonitis. Because drugs are more conveniently administered to CAPD patients IP, we tried the IP route. We also tested the intravenous route to compare its effectiveness with the IP route. We found that there is no difference between the two routes.
In conclusion, PTX inhibits the growth of and collagen synthesis by fibroblasts in vitro, and also decreases the fibrotic process in silica-induced peritonitis. Thus, PTX might have potential in preventing peritoneal fibrosis in CAPD patients. However, further study is necessary to prove its clinical effectiveness. 
